Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merck's pipeline. The magnitude of Prometheus' massive ...
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results